{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["13(11)"],"submitter":["Wang X"],"pubmed_abstract":["<h4>Background</h4>A phase 3 trial was conducted to evaluate the efficacy and safety of ongericimab, a monoclonal antibody that inhibits proprotein convertase subtilisin/kexin type 9, as an add-on treatment to optimized lipid-lowering therapy in Chinese patients with primary hypercholesterolemia and mixed dyslipidemia.<h4>Methods and results</h4>A total of 806 patients who were receiving stable and optimized lipid-lowering therapy but did not achieve their low-density lipoprotein cholesterol (LDL-C) targets were enrolled and randomly assigned in a 2:1:2:1 ratio to receive either ongericimab 150 mg or matching placebo every 2 weeks, or ongericimab 300 mg or matching placebo every 4 weeks for 52 weeks. Efficacy and safety were evaluated in 802 patients who received at least 1 dose of ongeric"],"journal":["Journal of the American Heart Association"],"pagination":["e033669"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11255649"],"repository":["biostudies-literature"],"pubmed_title":["Efficacy and Safety of Ongericimab in Chinese Patients With Primary Hypercholesterolemia and Mixed Dyslipidemia."],"pmcid":["PMC11255649"],"pubmed_authors":["Chen J","Zhu H","Wang G","Han Y","Qiu M","Sun Y","Bai X","Su G","Zhao Y","Cheng Z","Shao C","Yao Z","Ji X","Li S","Huang Z","Wang X","Lin J","Tang Y"],"additional_accession":[]},"is_claimable":false,"name":"Efficacy and Safety of Ongericimab in Chinese Patients With Primary Hypercholesterolemia and Mixed Dyslipidemia.","description":"<h4>Background</h4>A phase 3 trial was conducted to evaluate the efficacy and safety of ongericimab, a monoclonal antibody that inhibits proprotein convertase subtilisin/kexin type 9, as an add-on treatment to optimized lipid-lowering therapy in Chinese patients with primary hypercholesterolemia and mixed dyslipidemia.<h4>Methods and results</h4>A total of 806 patients who were receiving stable and optimized lipid-lowering therapy but did not achieve their low-density lipoprotein cholesterol (LDL-C) targets were enrolled and randomly assigned in a 2:1:2:1 ratio to receive either ongericimab 150 mg or matching placebo every 2 weeks, or ongericimab 300 mg or matching placebo every 4 weeks for 52 weeks. Efficacy and safety were evaluated in 802 patients who received at least 1 dose of ongeric","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Jun","modification":"2026-06-01T07:38:49.567Z","creation":"2025-04-06T17:11:46.519Z"},"accession":"S-EPMC11255649","cross_references":{"pubmed":["38818934"],"doi":["10.1161/JAHA.123.033669"]}}